SEC Form 4Coverage since Jun 29, 2026
$AKBA insider trading
Over the last 12 months, Akebia Therapeutics insiders reported no purchases and 1 sale totaling $62K across SEC Form 4 filings. 100% of the activity was filed under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $62K 1 event
- Events · 12m
- 1 Form 4 filings, grouped
- Insiders · 12m
- 1 distinct reporters
- 10b5-1 share
- 100% pre-arranged plans
Side
Price · $AKBA · 12Mvia TradingView
Top insiders · 12m
Ostrowski ErikSVP, CFO, CBO & Treasurer1× · $62K
All insider trades
1 event
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Jun 29, 2026 | Ostrowski ErikSVP, CFO, CBO & Treasurer · O | ▼ Sale | 56,019 | $1.11 | $62K | -8.3% | plan |
About Form 4
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $AKBA feed.